Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoral C2 monitoring versus Prograft trough monitoring after primary liver transplantation
NL-OMON24179Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclosporine, tacrolimus, basiliximab and prednisolone in Transplant rejection prophylaxis (2 arms), sponsored by Novartis. Primary endpoint: Incidence of biopsy-proven acute rejection. Started Dec 2002; status: active, not recruiting.
02
Drugs
cyclosporinetacrolimusbasiliximabprednisolone
03
Conditions
Transplant rejection prophylaxis
Beyond the preview
Go deeper on NL-OMON24179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24179.